Patents by Inventor Darren Wolfe

Darren Wolfe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250109411
    Abstract: Disclosed is a method for administering a transgene into a fibroblast in a subject comprising: a) providing a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein said recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide to be expressed in said fibroblast; and b) providing a pharmaceutically acceptable carrier, wherein said HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.
    Type: Application
    Filed: October 21, 2024
    Publication date: April 3, 2025
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Joseph C. Glorioso, III, Justus Cohen, Yoshitaka Miyagawa, David Krisky, James Wechuck, Darren Wolfe
  • Patent number: 12258133
    Abstract: A low profile pass-through electrical connector is designed for aerospace applications. The connector allows voltage and current to pass-thru a conductive wing surface, while maintaining a low profile height for aerodynamic performance considerations. Examples of applications of the electrical connector include power for thin film heaters and communication antennae applications.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: March 25, 2025
    Assignee: Battelle Memorial Institute
    Inventors: Brett Burton, Andrew Cox, Darren Wolfe
  • Patent number: 12064449
    Abstract: Disclosed is a composition comprising a microbe expressing ferritin. The composition also comprises elemental iron in an amount of at least 3% by weight on a dry matter basis of the microbe expressing ferritin and the elemental iron. Also disclosed are ingestibles, dietary supplements, and pharmaceutical compositions comprising the composition. Also disclosed are methods for treating a subject comprising administering the composition to the subject. Also disclosed are methods of altering the composition of the gut bacterial microbiome in a subject, the method comprising administering the composition to the subject.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: August 20, 2024
    Assignee: SIDERO BIOSCIENCE, LLC
    Inventors: Darren Wolfe, James Connor
  • Publication number: 20240252568
    Abstract: Disclosed herein are recombinant hosts comprising at least a first set of chromosomes and a second set of chromosomes, wherein at least one of the first set of chromosomes and the second set of chromosomes comprises a recombinant gene encoding ferritin or a homologue thereof. Also disclosed herein are recombinant hosts comprising a prototroph comprising a recombinant gene encoding ferritin or a homologue thereof. The recombinant hosts may be included in compositions, ingestible items, dietary supplements or pharmaceutical compositions. Also disclosed herein are methods of administering to a subject a composition of the present invention.
    Type: Application
    Filed: May 19, 2022
    Publication date: August 1, 2024
    Inventors: Ralph Keil, James Connor, Darren Wolfe
  • Publication number: 20240238335
    Abstract: A method comprising administering to a subject a composition comprising a microbe expressing ferritin or (a) a microbe expressing ferritin and (b) elemental iron, wherein the amount of elemental iron in the composition administered (1) to a subject not diagnosed with an iron deficiency disorder can exceed or is in excess of a dosage of elemental iron recommended by a nutritional authority or (2) to a subject diagnosed with an iron deficiency disorder can exceed or is in excess of a dosage of elemental iron recommended by a medical professional without an adverse effect. A method or a method of altering a composition of a gut bacterial microbiome in a subject comprising administering to a subject a composition comprising of a microbe or host expressing ferritin, with the proviso that when a daily dosage of ferritin in the composition is less than 200 milligrams/day, the composition is free of elemental iron.
    Type: Application
    Filed: May 19, 2022
    Publication date: July 18, 2024
    Inventors: James Connor, Ralph Keil, Darren Wolfe
  • Publication number: 20220213508
    Abstract: Disclosed is a method for administering a transgene into a fibroblast in a subject comprising: a) providing a herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein said recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide to be expressed in said fibroblast; and b) providing a pharmaceutically acceptable carrier; wherein said HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 7, 2022
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Joseph C. Glorioso, III, Justus Cohen, Yoshitaka Miyagawa, David Krisky, James Wechuck, Darren Wolfe
  • Publication number: 20210220396
    Abstract: Disclosed is a composition comprising a microbe expressing ferritin. The composition also comprises elemental iron in an amount of at least 3% by weight on a dry matter basis of the microbe expressing ferritin and the elemental iron. Also disclosed are ingestibles, dietary supplements, and pharmaceutical compositions comprising the composition. Also disclosed are methods for treating a subject comprising administering the composition to the subject. Also disclosed are methods of altering the composition of the gut bacterial microbiome in a subject, the method comprising administering the composition to the subject.
    Type: Application
    Filed: June 4, 2019
    Publication date: July 22, 2021
    Inventors: Darren Wolfe, James Connor
  • Publication number: 20190276845
    Abstract: In one embodiment, the invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in non-complementing cells. The invention also relates to viral stocks of the inventive vectors, compositions thereof suitable for use therapeutically or for in vitro applications, and methods relating thereto. In another aspect, the invention provides a complementing cell engineered to express ICP4 and ICP27 when the cell is infected with HSV for the production of the inventive vector.
    Type: Application
    Filed: November 26, 2018
    Publication date: September 12, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Joseph C. Glorioso, III, Justus Cohen, Yoshitaka Miyagawa, David Krisky, James Wechuck, Darren Wolfe
  • Patent number: 10174341
    Abstract: The invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in non-complementing cells. The disclosed vectors include vectors having deletions in the genes ICP0, ICP4, TCP22, TCP27 and TCP47, or alternative inactivating mutations, or vectors which express one or more of these genes with modified kinetics. The invention also relates to viral stocks of the inventive vectors, compositions thereof suitable for use therapeutically or for in vitro applications, and methods relating thereto. In another aspect, the invention provides a complementing cell, in particular a U20S cell, engineered to express ICP4 and ICP27 when the cell is infected with HSV for the production of the inventive vector. Said cells are disclosed as naturally complementing ICP0.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: January 8, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Joseph C. Glorioso, III, Justus Cohen, Yoshitaka Miyagawa, David Krisky, James Wechuck, Darren Wolfe
  • Patent number: 9873516
    Abstract: A low profile pass-through electrical connector is designed for aerospace applications. The connector allows voltage and current to pass-thru a conductive wing surface, while maintaining a low profile height for aerodynamic performance considerations. Examples of applications of the electrical connector include power for thin film heaters and communication antennae applications.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: January 23, 2018
    Assignee: Battelle Memorial Institute
    Inventors: Brett Burton, Andrew Cox, Darren Wolfe
  • Publication number: 20170305561
    Abstract: A low profile pass-through electrical connector is designed for aerospace applications. The connector allows voltage and current to pass-thru a conductive wing surface, while maintaining a low profile height for aerodynamic performance considerations. Examples of applications of the electrical connector include power for thin film heaters and communication antennae applications.
    Type: Application
    Filed: April 17, 2017
    Publication date: October 26, 2017
    Inventors: Brett Burton, Andrew Cox, Darren Wolfe
  • Patent number: 9623975
    Abstract: A low profile pass-through electrical connector is designed for aerospace applications. The connector allows voltage and current to pass-thru a conductive wing surface, while maintaining a low profile height for aerodynamic performance considerations. Examples of applications of the electrical connector include power for thin film heaters and communication antennae applications.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: April 18, 2017
    Assignee: Battelle Memorial Institute
    Inventors: Brett Burton, Andrew Cox, Darren Wolfe
  • Publication number: 20160153000
    Abstract: The invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in non-complementing cells. The disclosed vectors include vectors having deletions in the genes ICP0, ICP4, TCP22, TCP27 and TCP47, or alternative inactivating mutations, or vectors which express one or more of these genes with modified kinetics. The invention also relates to viral stocks of the inventive vectors, compositions thereof suitable for use therapeutically or for in vitro applications, and methods relating thereto. In another aspect, the invention provides a complementing cell, in particular a U20S cell, engineered to express ICP4 and ICP27 when the cell is infected with HSV for the production of the inventive vector. Said cells are disclosed as naturally complementing ICP0.
    Type: Application
    Filed: July 17, 2014
    Publication date: June 2, 2016
    Inventors: Joseph C. Glorioso, Justus Cohen, Yoshitaka Miyagawa, David Krisky, James Wechuck, Darren Wolfe
  • Publication number: 20140256801
    Abstract: The invention provides a method of treating spinal cord injury pain or peripheral neuropathic pain in a mammal comprising administering to a mammal a vector comprising a nucleotide sequence encoding a glutamic acid decarboxylase (GAD) protein in an amount effective to treat spinal cord injury pain or peripheral neuropathic pain.
    Type: Application
    Filed: April 22, 2014
    Publication date: September 11, 2014
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The US Government as represented by the Department of Veterans Affairs
    Inventors: Joseph C. Glorioso, David J. Fink, Darren Wolfe, David Krisky
  • Publication number: 20140151352
    Abstract: A low profile pass-through electrical connector is designed for aerospace applications. The connector allows voltage and current to pass-thru a conductive wing surface, while maintaining a low profile height for aerodynamic performance considerations. Examples of applications of the electrical connector include power for thin film heaters and communication antennae applications.
    Type: Application
    Filed: June 3, 2013
    Publication date: June 5, 2014
    Inventors: Brett Burton, Andrew Cox, Darren Wolfe
  • Publication number: 20140015733
    Abstract: A low profile pass-through electrical connector is designed for aerospace applications. The connector allows voltage and current to pass-thru a conductive wing surface, while maintaining a low profile height for aerodynamic performance considerations. Examples of applications of the electrical connector include power for thin film heaters and communication antennae applications.
    Type: Application
    Filed: June 3, 2013
    Publication date: January 16, 2014
    Inventors: Brett BURTON, Andrew COX, Darren WOLFE
  • Patent number: 8309349
    Abstract: The invention provides a cell line complementing HSV ICP4, ICP27, and UL55 genes.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: November 13, 2012
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Joseph C. Glorioso, Darren Wolfe, David Krisky
  • Patent number: 8148146
    Abstract: The invention provides a cell line complementing HSV ICP4, ICP27, and UL55 genes.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: April 3, 2012
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Joseph C. Glorioso, Darren Wolfe, David Krisky
  • Publication number: 20090238807
    Abstract: The invention provides a cell line complementing HSV ICP4, ICP27, and UL55 genes.
    Type: Application
    Filed: April 3, 2009
    Publication date: September 24, 2009
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Joseph C. Glorioso, Darren Wolfe, David Krisky
  • Patent number: 7531167
    Abstract: The invention provides a herpes simplex virus vector comprising deletions in ICP4, ICP27, and UL55.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: May 12, 2009
    Assignee: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Joseph C. Glorioso, Darren Wolfe, David Krisky